Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo


Por: Rotllan N., Llaverías G., Julve J., Jauhiainen M., Calpe-Berdiel L., Hernández C., Simó R., Blanco-Vaca F., Escolà-Gil J.C.

Publicada: 1 ene 2011
Resumen:
Gemfibrozil and fenofibrate, two of the fibrates most used in clinical practice, raise HDL cholesterol (HDLc) and are thought to reduce the risk of atherosclerotic cardiovascular disease. These drugs act as PPARa agonists and upregulate the expression of genes crucial in reverse cholesterol transport (RCT). In the present study, we determined the effects of these two fibrates on RCT from macrophages to feces in vivo in human apoA-I transgenic (hApoA-ITg) mice. [3H]cholesterol-labeled mouse macrophages were injected intraperitoneally into hApoA-ITg mice treated with intragastric doses of fenofibrate, gemfibrozil or a vehicle solution for 17 days, and radioactivity was determined in plasma, liver and feces. Fenofibrate, but not gemfibrozil, enhanced [3H]cholesterol flux to plasma and feces of female hApoA-ITg mice. Fenofibrate significantly increased plasma HDLc, HDL phospholipids, hApoA-I levels and phospholipid transfer protein activity, whereas these parameters were not altered by gemfibrozil treatment. Unlike gemfibrozil, fenofibrate also induced the generation of larger HDL particles, which were more enriched in cholesteryl esters, together with higher potential to generate preß-HDL formation and caused a significant increase in [ 3H]cholesterol efflux to plasma. Our findings demonstrate that fenofibrate promotes RCT from macrophages to feces in vivo and, thus, highlight a differential action of this fibrate on HDL. © 2010 Elsevier B.V. All rights reserved.

Filiaciones:
Rotllan N.:
 IIB Sant Pau., 08025 Barcelona, Spain

 CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, 08036 Barcelona, Spain

Llaverías G.:
 IIB Sant Pau., 08025 Barcelona, Spain

 CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, 08036 Barcelona, Spain

Julve J.:
 IIB Sant Pau., 08025 Barcelona, Spain

 CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, 08036 Barcelona, Spain

Jauhiainen M.:
 National Institute for Health and Welfare, FIMM Institute for Molecular Medicine Finland, Biomedicum, Helsinki, Finland

Calpe-Berdiel L.:
 IIB Sant Pau., 08025 Barcelona, Spain

Hernández C.:
 CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, 08036 Barcelona, Spain

 Diabetes and Metabolism Research Unit., Inst. de Recerca Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, 08035 Barcelona, Spain

Simó R.:
 CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, 08036 Barcelona, Spain

 Diabetes and Metabolism Research Unit., Inst. de Recerca Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, 08035 Barcelona, Spain

Blanco-Vaca F.:
 IIB Sant Pau., 08025 Barcelona, Spain

 CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, 08036 Barcelona, Spain

 Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain

Escolà-Gil J.C.:
 IIB Sant Pau., 08025 Barcelona, Spain

 CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, 08036 Barcelona, Spain
ISSN: 13881981
Editorial
ELSEVIER, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 1811 Número: 2
Páginas: 104-110
WOS Id: 000286998500006
ID de PubMed: 21126601

MÉTRICAS